Posters

Tardive dyskinesia (TD) is a hyperkinetic movement disorder resulting from chronic exposure to antipsychotics. TD is underdiagnosed; understanding barriers to diagnosis is an unmet need. We aimed to understand patient perspectives on barriers to and determinants of TD diagnosis.

There is limited understanding of how tardive dyskinesia (TD) affects individuals with different underlying psychiatric conditions.

Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. Dysphagia is common in both disorders, and alternative modes for oral medication administration are available with 2 approved valbenazine formulations.

Valbenazine is a once-daily medication approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease. Data from a 48-week, open-label study of valbenazine in patients with TD (KINECT 4 [NCT02405091]) were analyzed to assess a potential threshold for remission of TD while taking valbenazine.

Tardive dyskinesia (TD) can profoundly impact patients’ daily functioning and overall quality of life, making appropriate diagnosis and management critical. This study aimed to identify changes in practice patterns, knowledge, and barriers among United States (US) psychiatry clinicians in managing patients with TD over time and to determine how continuing medical education (CME) has impacted clinicians' adherence to guideline- and evidence-based care.